Gebruikersprofielen voor "Span, P. "
span pGeverifieerd e-mailadres voor radboudumc.nl Geciteerd door 41898 |
Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy
TWH Meijer, JHAM Kaanders, PN Span, J Bussink - Clinical cancer research, 2012 - AACR
Radiotherapy, an important treatment modality in oncology, kills cells through induction of
oxidative stress. However, malignant tumors vary in their response to irradiation as a …
oxidative stress. However, malignant tumors vary in their response to irradiation as a …
[PDF][PDF] Genomic actions of estrogen receptor?: what are the targets and how are they regulated?
WJ Welboren, FCGJ Sweep, PN Span… - Endocrine-related …, 2009 - researchgate.net
The estrogen receptor a (ERa) is a ligand-dependent transcription factor that regulates a large
number of genes in many different target tissues and is important in the development and …
number of genes in many different target tissues and is important in the development and …
[HTML][HTML] Molecular aspects of tumour hypoxia
SE Rademakers, PN Span, JHAM Kaanders… - Molecular …, 2008 - Elsevier
Hypoxia is an important feature of the microenvironment of a wide range of solid tumours. Its
critical role in radio- and chemoresistance and its significance as an adverse prognostic …
critical role in radio- and chemoresistance and its significance as an adverse prognostic …
Signatures of mutational processes in human cancer
All cancers are caused by somatic mutations; however, understanding of the biological
processes generating these mutations is limited. The catalogue of somatic mutations from a …
processes generating these mutations is limited. The catalogue of somatic mutations from a …
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
We analysed whole-genome sequences of 560 breast cancers to advance understanding of
the driver mutations conferring clonal advantage and the mutational processes generating …
the driver mutations conferring clonal advantage and the mutational processes generating …
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Approximately 1–5% of breast cancers are attributed to inherited mutations in BRCA1 or
BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other …
BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other …
Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
Introduction The human genome is peppered with mobile repetitive elements called long
interspersed nuclear element–1 (L1) retrotransposons. Propagating through RNA and cDNA …
interspersed nuclear element–1 (L1) retrotransposons. Propagating through RNA and cDNA …
[HTML][HTML] Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes
JB de Kok, RW Roelofs, BA Giesendorf… - Laboratory …, 2005 - Elsevier
For interpretation of quantitative gene expression measurements in clinical tumor samples,
a normalizer is necessary to correct expression data for differences in cellular input, RNA …
a normalizer is necessary to correct expression data for differences in cellular input, RNA …
Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial
GO Janssens, SE Rademakers, CH Terhaard… - Journal of clinical …, 2012 - ascopubs.org
Purpose To report the results from a randomized trial comparing accelerated radiotherapy (AR)
with accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON) in …
with accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON) in …
ChIP‐Seq of ERα and RNA polymerase II defines genes differentially responding to ligands
WJ Welboren, MA Van Driel… - The EMBO …, 2009 - embopress.org
We used ChIP‐Seq to map ERα‐binding sites and to profile changes in RNA polymerase II (RNAPII)
occupancy in MCF‐7 cells in response to estradiol (E2), tamoxifen or fulvestrant. …
occupancy in MCF‐7 cells in response to estradiol (E2), tamoxifen or fulvestrant. …